HomeInsightsStock Comparison

Ambalal Sarabhai Enterprises Ltd vs Onesource Specialty Pharma Ltd Stock Comparison

Ambalal Sarabhai Enterprises Ltd vs Onesource Specialty Pharma Ltd Stock Comparison

Last Updated on: Jun 08, 2025

Key Highlights

  • The Latest Trading Price of Ambalal Sarabhai Enterprises Ltd is ₹ 35.88 as of 06 Jun 15:30.
  • The P/E Ratio of Ambalal Sarabhai Enterprises Ltd changed from 10.4 on March 2020 to 61.5 on March 2024 . This represents a CAGR of 42.68% over 5 yearsThe P/E Ratio of OneSource Specialty Pharma Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The Market Cap of Ambalal Sarabhai Enterprises Ltd changed from ₹ 145.99 crore on March 2020 to ₹ 348.53 crore on March 2024 . This represents a CAGR of 19.01% over 5 yearsThe Market Cap of OneSource Specialty Pharma Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The revenue of Ambalal Sarabhai Enterprises Ltd for the Mar '25 is ₹ 66.45 crore as compare to the Dec '24 revenue of ₹ 51.73 crore. This represent the growth of 28.46% The revenue of OneSource Specialty Pharma Ltd for the Mar '25 is ₹ 428.84 crore as compare to the Dec '24 revenue of ₹ 399.28 crore. This represent the growth of 7.4%.
  • The ebitda of Ambalal Sarabhai Enterprises Ltd for the Mar '25 is ₹ -0.07 crore as compare to the Dec '24 ebitda of ₹ 5.06 crore. This represent the decline of -101% The ebitda of OneSource Specialty Pharma Ltd for the Mar '25 is ₹ 184.72 crore as compare to the Dec '24 ebitda of ₹ 48.08 crore. This represent the growth of 284.19%.
  • The net profit of Ambalal Sarabhai Enterprises Ltd changed from ₹ -4.87 crore to ₹ -0.27 crore over 8 quarters. This represents a CAGR of -76.45% The net profit of OneSource Specialty Pharma Ltd changed from ₹ -107 crore to ₹ 98.5 crore over 8 quarters. This represents a CAGR of NaN% .
  • The Dividend Payout of Ambalal Sarabhai Enterprises Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of OneSource Specialty Pharma Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Ambalal Sarabhai Enterprises Ltd

  • Ambalal Sarabhai Enterprises Ltd., incorporated on June 5, 1978, houses a range of companies across multi-dimensional businesses.
  • Each subsidiary is a distinct entity contributing its unique expertise and capabilities.
  • It is one of the oldest pharmaceutical health care companies in India, and today through its group companies it manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and internationally.
  • ASE's strength is to lead with cutting edge technology by creating strategic technology tie-ups and collaborative partnerships through our broad national and international networks The Company produces a range of bulk drugs, pharmaceutical preparations and electronic instruments.
  • It operates in two segments, pharmaceuticals and electronics.

About OneSource Specialty Pharma Ltd

  • Onesource Specialty Pharma Limited was incorporated as a Private Limited Company, with the name and style of Inbiopro Solutions Private Limited' dated June 12, 2007, was issued by the Registrar of Companies, Karnataka at Bangalore.
  • The Company name was then changed to Stelis Biopharma Private Limited', pursuant to a Scheme of Amalgamation and a Certificate of Incorporation dated December 24, 2014, was issued by the Registrar of Companies.
  • The status of the Company was then converted from a Private Limited Company to a Public Limited Company, and renamed as Stelis Biopharma Limited' dated July 31, 2021,.
  • Subsequently, the name was changed to its present Onesource Specialty Pharma Limited' on February 13, 2024, and a fresh Certificate of Incorporation dated February 13, 2024, was issued by the Registrar of Companies, Karnataka at Bangalore.

Ambalal Sarabhai Enterprises Ltd News Hub

News

Ambalal Sarabhai Enterprises schedules AGM

Ambalal Sarabhai Enterprises announced that the 47th Annual General Meeting(AGM) of the co...

Read more

07 Jun 2025 09:30

News

Ambalal Sarabhai Enterprises to table results

Ambalal Sarabhai Enterprises will hold a meeting of the Board of Directors of the Company ...

Read more

23 May 2025 17:45

News

Ambalal Sarabhai Enterprises to convene board meeting

Ambalal Sarabhai Enterprises will hold a meeting of the Board of Directors of the Company ...

Read more

06 Feb 2025 11:55

News

Ambalal Sarabhai Enterprises to convene board meeting

Ambalal Sarabhai Enterprises will hold a meeting of the Board of Directors of the Company ...

Read more

05 Nov 2024 13:38

News

Ambalal Sarabhai Enterprises announces board meeting date

Ambalal Sarabhai Enterprises will hold a meeting of the Board of Directors of the Company ...

Read more

03 Aug 2024 10:31

News

Ambalal Sarabhai Enterprises to conduct AGM

Ambalal Sarabhai Enterprises announced that the 46th Annual General Meeting (AGM) of the c...

Read more

29 May 2024 15:01

OneSource Specialty Pharma Ltd News Hub

News

OneSource receives ratings action from India Ratings & Research

OneSource Specialty Pharma announced that India Ratings & Research has assigned the credit...

Read more

04 Jun 2025 12:48

News

OneSource Specialty Pharma to convene board meeting

OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on...

Read more

30 Apr 2025 11:35

News

OneSource Specialty Pharma to convene board meeting

OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on...

Read more

25 Jan 2025 10:23

News

Shares of Onesource Specialty Pharma list in T Group

The equity shares of Onesource Specialty Pharma (Scrip Code: 544292) are listed effective ...

Read more

24 Jan 2025 09:22

SWOT Analysis Of OneSource Specialty Pharma Ltd

Strength

0

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Ambalal Sarabhai Enterprises Ltd

Strength

1

S

Weakness

0

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Ambalal Sarabhai Enterprises Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Ambalal Sarabhai Enterprises Ltd and OneSource Specialty Pharma Ltd

Which company has a larger market capitalization, Ambalal Sarabhai Enterprises Ltd or OneSource Specialty Pharma Ltd?

Market cap of Ambalal Sarabhai Enterprises Ltd is 274 Cr while Market cap of OneSource Specialty Pharma Ltd is 22,188 Cr

What are the key factors driving the stock performance of Ambalal Sarabhai Enterprises Ltd and OneSource Specialty Pharma Ltd?

The stock performance of Ambalal Sarabhai Enterprises Ltd and OneSource Specialty Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ambalal Sarabhai Enterprises Ltd and OneSource Specialty Pharma Ltd?

As of June 8, 2025, the Ambalal Sarabhai Enterprises Ltd stock price is INR ₹35.88. On the other hand, OneSource Specialty Pharma Ltd stock price is INR ₹1938.9.

How do dividend payouts of Ambalal Sarabhai Enterprises Ltd and OneSource Specialty Pharma Ltd compare?

To compare the dividend payouts of Ambalal Sarabhai Enterprises Ltd and OneSource Specialty Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions